Competition for targets, a tougher stance from regulators and uneven performance are likely to create an uneasy environment for healthcare special purpose acquisition companies in 2022, S&P Global reports. A total of 107 SPACs that listed parts of the healthcare industry as their intended target went public in 2021, according to S&P Global Market Intelligence data. Deal volume picked up in the last four months of the year, with 23 IPOs in November and December. That uptick in volume means more competition for healthcare companies that are mature enough to go public. Read more.
Related Posts
Barrows Hotel Enterprises Considers SPAC Merger
With a SPAC Merger, the company estimates it could be worth over $500 million.
SPAC Warrant Resolution Said to be in Works: Report
Legal and accounting specialists are developing a type of warrant that can be treated as equity but it’s weeks away and needs SEC approval, CFO Dive reports.
SEC chair Gensler Worries ‘People will be Hurt’ Without Crypto, SPAC Regulations: Report
The SEC chairman in an interview said he wants to ensure investors “are getting a full and fair disclosure” when investing in cryptocurrencies and SPACs.
Branson’s $520 Million Virgin Money Exit Exposes SPAC Scars
Overall, Branson’s sinking stock holdings have resulted in his net worth falling by roughly half since mid-2022 to about $3 billion.